 astrazeneca hit drug failure share angloswedish drug closed 8 uk trade failure iressa drug major clinical trial lung cancer drug significantly prolong survival patient disease setback group follows rejection u october anticoagulant pill exanta meanwhile another major money spinner cholesterol drug crestor facing mounting safety concern would two three blockbuster drug meant power company forward failing weve got risk crestor said nick turner analyst broker jefferies astrazeneca hoped pitch iressa drug rival medicine tarceva iressa proved better placebo extending life trial involving 1692 patient tarceva made osi pharmaceutical genentech roche already proved successful helping prolong life lung cancer patient aztrazeneca appointed new executive director board john patterson charge drug development company said mr patterson would make substantial change clinical organisation process determined improve development regulatory performance restore confidence company value shareholder said chief executive tom mckillop